Glycosylation profiling of triple-negative breast cancer: clinical and immune correlations and identification of LMAN1L as a biomarker and therapeutic target

作者：Qianru Yu, Hanyi Zhong, Xinhao Zhu, Chang Liu, Xin Zhang, Jiao Wang, Z. Li, Songchang Shi, Haoran Zhao, Ci-Xiang Zhou, Qian Zhao · 发表于：Frontiers in Immunology · 年份：2025 · DOI：10.3389/fimmu.2024.1521930 · 被引用次数：3 · 研究领域：Glycosylation and Glycoproteins Research、Clusterin in disease pathology、Galectins and Cancer Biology

Introduction Breast cancer (BC) is the most prevalent malignant tumor in women, with triple-negative breast cancer (TNBC) showing the poorest prognosis among all subtypes. Glycosylation is increasingly recognized as a critical biomarker in the tumor microenvironment, particularly in BC. However, the glycosylation-related genes associated with TNBC have not yet been defined. Additionally, their characteristics and relationship with prognosis have not been deeply investigated. Methods Transcriptomic analyses were used to identify a glycosylation-related signature (GRS) associated with TNBC prognosis. A machine learning-based prediction model was constructed and validated across multiple independent datasets. The model's predictive capability was extended to evaluate the prognosis of TNBC individuals, tumor immune microenvironment and immunotherapy response. LMAN1L (Lectin, Mannose Binding 1 Like) was identified as a novel prognostic marker in TNBC, and its biological effects were validated through experimental assays. Results The GRS showed significant prognostic relevance for TNBC patients. The risk model effectively predicted molecular features, including immune cell infiltration and potential responses to immunotherapy. Experimental validation confirmed LMAN1L as a novel glycosylation-related prognostic gene, with low expression significantly inhibiting TNBC cell proliferation and migration. Discussion Our GRS risk model demonstrates robust predictive capability for TNBC pro...